MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, IRWD had $126,897K increase in cash & cash equivalents over the period. $127,010K in free cash flow.

Cash Flow Overview

Change in Cash
$126,897K
Free Cash flow
$127,010K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Deferred income taxes
    • Accounts receivable, net
    • Net income
    • Others
Negative Cash Flow Breakdown
    • Accrued research and development...
    • Operating lease liabilities
    • Effect of exchange rate changes ...
    • Purchases of property and equipm...

Cash Flow
2025-12-31
Net income
24,017
Depreciation and amortization
1,881
Loss on disposal of property and equipment
-89
Share-based compensation expense
17,250
Non-cash interest expense
1,668
Non-cash lease expense
1,688
Deferred income taxes
40,801
Accounts receivable, net
-35,148
Prepaid expenses and other current assets
-367
Other assets
-447
Accounts payable and accrued expenses
6,201
Accrued research and development costs
-4,106
Operating lease liabilities
-2,371
Other liabilities
3,964
Net cash provided by operating activities
127,044
Purchases of property and equipment
34
Net cash used in investing activities
-34
Proceeds from exercise of stock options and employee stock purchase plan
216
Net cash provided by (used in) financing activities
216
Effect of exchange rate changes on cash and cash equivalents
-329
Net increase (decrease) in cash and cash equivalents
126,897
Cash and cash equivalents, beginning of period
88,559
Cash and cash equivalents, end of period
215,456
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Deferred income taxes$40,801K Accounts receivable, net-$35,148K Net income$24,017K Share-based compensationexpense$17,250K Accounts payable andaccrued expenses$6,201K Other liabilities$3,964K Proceeds from exercise ofstock options and...$216K Depreciation andamortization$1,881K Non-cash lease expense$1,688K Non-cash interestexpense$1,668K Other assets-$447K Prepaid expenses andother current assets-$367K Loss on disposal ofproperty and equipment-$89K Net cash provided byoperating activities$127,044K Net cash provided by(used in) financing...$216K Canceled cashflow$6,477K Net increase(decrease) in cash and cash...$126,897K Canceled cashflow$363K Accrued research anddevelopment costs-$4,106K Operating leaseliabilities-$2,371K Effect of exchange ratechanges on cash and cash...-$329K Net cash used ininvesting activities-$34K Purchases of property andequipment$34K

IRONWOOD PHARMACEUTICALS INC (IRWD)

IRONWOOD PHARMACEUTICALS INC (IRWD)